a public good project by the
Synthesis
Company
of California

© 2026

Yu Chung Wang | doi.page

0 works0 citations0 h-index

Google Scholar OpenAlex

Yu Chung Wang

Amgen (United States)(US)

Research Areas

Cancer-related Molecular Pathways, Ubiquitin and proteasome pathways, Microtubule and mitosis dynamics, Cancer, Hypoxia, and Metabolism

Most-Cited Works

→ Discovery of AMG 232, a Potent, Selective, and Orally Bioavailable MDM2–p53 Inhibitor in Clinical Development(2014)291 cited
→ Discovery of AM-7209, a Potent and Selective 4-Amidobenzoic Acid Inhibitor of the MDM2–p53 Interaction(2014)47 cited